Rituximab Clinical Trial Q&A, Developed by the ME AssociationProHealthby ME Association Following is an informative Q&A on the rituximab ME/CFS trial, the drug, and future research issues posted Oct 20 by Tony Britton & Dr. Charles Shepherd…
Business Wire (Pressemitteilung)Biogen Idec und Abbott präsentieren positive Daten für Daclizumab HYP aus der …Business Wire (Pressemitteilung)SELECT ist die erste von zwei Zulassungsstudien, mit denen das Prüfpräparat Daclizumab High-Yield Proce…
The Zacks Analyst Blog Highlights: Abbott Labs, Bristol-Myers Squibb, Biogen …Sacramento BeeAbbott Labs, along with partner Biogen (Nasdaq: BIIB), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis (RR…
SCLEROSI MULTIPLA – Biogen Idec-Abbott. DACLIZUMAB HYP: POSITIVI I RISULTATI …SalusI dati relativi allo studio SELECT sono stati divulgati oggi, sabato 22 ottobre 2011, durante la presentazione intitolata “Uno studio randomizzato, in doppio cieco, …
Business Wire (persbericht)Samenvatting: Biogen Idec en Abbott presenteren positieve resultaten voor …Business Wire (persbericht)… resultaten bekend van het SELECT fase 2b onderzoek, het eerste van twee registrationele onderzoeken ter evaluatie van…
eYugoslavia.comAbbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b …News-Medical.netToday Biogen Idec (NASDAQ: BIIB) and Abbott (NYSE: ABT) announced additional results from the SELECT Phase 2b trial, the first of two registr…
Abbott Laboratories : Biogen Idec et Abbott présentent les résultats positifs …Zonebourse.comLe DAC HYP (Daclizumab high-yield process) est une formulation du daclizumab à administration sous-cutanée qui constitue une thérapie expérimentale pou…
eYugoslavia.comBiogen Idec, Abbott Say SELECT Phase 2B Trial For RRMS Compound Met Primary GoalRTT News(RTTNews) – Biotechnology firms Biogen Idec Inc. (BIIB: News ) and Abbott Laboratories (ABT: News ) announced Saturday that the investigational compo…
EON: Enhanced Online News (press release)Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select …EON: Enhanced Online News (press release)The SELECT data was presented in a late-breaking platform presentation, called A randomized…
eYugoslavia.comBiogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select …Victoria Times ColonistToday Biogen Idec (NASDAQ: BIIB) and Abbott (NYSE: ABT) announced additional results from the SELECT Phase 2b trial, the first of two r…